If the Notch2 missense mutations identified in these ovarian cancer TO cell lines renders the Notch2 protein nonfunctional, then a dysregulated Notch2 signaling pathway may be partially responsible for the observed carboplatin sensitivity. This evidence concerns the gene NOTCH2 and ovarian cancer.